Ralliant (NYSE:RAL) Downgraded by Wall Street Zen to “Hold”

Ralliant (NYSE:RAL) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Other equities research analysts also recently issued reports about the stock. Zacks Research raised shares of Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Morgan Stanley upped their price objective on shares of Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. TD Cowen upped their price objective on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 20th. Truist Financial reaffirmed a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Finally, Oppenheimer upped their price objective on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $64.50.

Ralliant Price Performance

Shares of NYSE:RAL opened at $61.84 on Friday. The company’s 50-day moving average is $48.80 and its 200 day moving average is $48.68. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The company has a market capitalization of $6.92 billion and a P/E ratio of -5.65. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $62.95.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities research analysts forecast that Ralliant will post 2.64 earnings per share for the current year.

Insider Activity at Ralliant

In other news, SVP Karen M. Bick sold 5,485 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total value of $246,825.00. Following the transaction, the senior vice president owned 46,756 shares of the company’s stock, valued at $2,104,020. This represents a 10.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers purchased a new stake in Ralliant during the second quarter valued at about $700,000. Russell Investments Group Ltd. purchased a new position in shares of Ralliant in the 2nd quarter worth about $1,465,000. EverSource Wealth Advisors LLC purchased a new position in shares of Ralliant in the 2nd quarter worth about $39,000. First Trust Advisors LP bought a new position in shares of Ralliant during the 2nd quarter valued at about $2,013,000. Finally, Federated Hermes Inc. bought a new position in shares of Ralliant during the 2nd quarter valued at about $326,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.